Empagliflozin · Jardiance

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Atherosclerotic Cardiovascular Disease, Heart Failure, Chronic Kidney Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Treatment of type 2 diabetes mellitus
Product first approved 2014PMDA
EU
  • Type 2 diabetes mellitus Jardiance is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance in addition to other medicinal products for the treatment of diabetes For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. Heart failure Jardiance is indicated in adults for the treatment...
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (77)
Chronic Kidney Disease
NCT07107945 · Boehringer Ingelheim
2025-12-09 – 2028-04-14 · Chronic Kidney Disease
What this study did
NCT05715814 · University Health Network, Toronto
2024-09-01 – 2027-12-01 · Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors, Kidney Dysfunction, Residual Kidney Function
What this study did
NCT03933956 · Singapore General Hospital
2020-01-09 – 2020-08-01 · Diabetic Nephropathies
What this study did
NCT03173963 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2017-05-27 – 2020-02-21 · Diabetic Kidney Disease, Diabetes Mellitus Type 2
What this study did
Heart Failure
NCT05392764 · Juntendo University
2022-09-10 – 2027-12-31 · Acute Heart Failure
What this study did
NCT06024746 · Colorado Prevention Center
2024-07-09 – 2027-11 · Heart Failure
What this study did
NCT07038356 · Christian Schulze
2025-12-08 – 2027-06-30 · Acute Decompensated Heart Failure (ADHF)
What this study did
NCT05182658 · National Institute of Cardiology, Warsaw, Poland
2022-06-01 – 2026-11-30 · Hypertrophic Cardiomyopathy, Heart Failure
What this study did
NCT05776043 · Medical University of Warsaw
2022-03-15 – 2025-12-31 · Acute Decompensated Heart Failure
What this study did
NCT06683053 · Conrado Roberto Hoffmann Filho
2023-03-17 – 2025-02-28 · Congestive Heart Failure (CHF)
What this study did
NCT05556044 · Chinese University of Hong Kong
2022-09-27 – 2024-05-31 · Acute Heart Failure
What this study did
NCT04509674 · Boehringer Ingelheim
2020-12-16 – 2023-11-05 · Myocardial Infarction
What this study did
NCT03087773 · Medical University of Graz
2017-05-11 – 2022-05-17 · Acute Myocardial Infarction
What this study did
NCT04157751 · Boehringer Ingelheim
2020-05-18 – 2021-06-02 · Heart Failure
What this study did
NCT03332212 · Boehringer Ingelheim
2018-03-01 – 2020-05-28 · Heart Failure
What this study did
Type 2 Diabetes
NCT06083675 · Novo Nordisk A/S
2024-01-26 – 2027-05-28 · Diabetes Mellitus, Type 2
What this study did
NCT07093476 · Celltrion
2025-07-18 – 2027-04 · T2DM, Diabete Type 2, DM
What this study did
NCT06952231 · University of Lahore
2024-05-21 – 2025-01-05 · Diabetes Mellitus
What this study did
NCT05545800 · Xiangya Hospital of Central South University
2022-09-01 – 2024-06-01 · Type 2 Diabetes Mellitus
What this study did
NCT05109949 · Centro Universitario de Ciencias de la Salud, Mexico
2020-03-30 – 2022-08-01 · Diabetes Mellitus Type 2 Without Complication
What this study did
NCT04233801 · Boehringer Ingelheim
2020-04-15 – 2022-03-10 · Diabetes Mellitus, Type 2
What this study did
NCT04195243 · Centro Universitario de Ciencias de la Salud, Mexico
2019-12-02 – 2020-12-30 · Type 2 Diabetes Mellitus
What this study did
NCT03151343 · Caroline M Kistorp
2017-03-29 – 2020-05-22 · Type2 Diabetes Mellitus
What this study did
NCT03118336 · Assistance Publique Hopitaux De Marseille
2017-06-16 – 2020-02-07 · Type 2 Diabetes
What this study did
NCT02752113 · Institut für Pharmakologie und Präventive Medizin
2016-04 – 2019-05 · Diabetes Mellitus Type 2
What this study did
NCT03060980 · Intarcia Therapeutics
2017-03-03 – 2018-01-26 · Diabetes Mellitus, Type 2
What this study did
NCT02489968 · Boehringer Ingelheim
2015-05-12 – 2017-06-16 · Diabetes Mellitus, Type 2
What this study did
NCT02182830 · Boehringer Ingelheim
2014-07-25 – 2017-05-18 · Diabetes Mellitus, Type 2, Hypertension
What this study did
NCT02453555 · Boehringer Ingelheim
2015-05-14 – 2017-03-27 · Diabetes Mellitus, Type 2
What this study did
NCT01984606 · Boehringer Ingelheim
2015-01 – 2017-02 · Diabetes Mellitus, Type 2
What this study did
NCT02471963 · University of Erlangen-Nürnberg Medical School
2014-12 – 2016-06 · Diabetes Mellitus Type 2
What this study did
NCT01167881 · Boehringer Ingelheim
2010-08 – 2015-08 · Diabetes Mellitus, Type 2
What this study did
NCT01734785 · Boehringer Ingelheim
2013-02-08 – 2015-03-23 · Diabetes Mellitus, Type 2
What this study did
NCT01778049 · Boehringer Ingelheim
2013-01 – 2015-03 · Diabetes Mellitus, Type 2
What this study did
NCT01719003 · Boehringer Ingelheim
2012-10 – 2014-12 · Diabetes Mellitus, Type 2, Hyperglycemia
What this study did
NCT01947855 · Boehringer Ingelheim
2013-09 – 2013-12 · Diabetes Mellitus, Type 2
What this study did
NCT01289990 · Boehringer Ingelheim
2011-02 – 2013-05 · Diabetes Mellitus, Type 2
What this study did
NCT01368081 · Boehringer Ingelheim
2011-05 – 2013-04 · Diabetes Mellitus, Type 2
What this study did
NCT01164501 · Boehringer Ingelheim
2010-07 – 2012-07 · Diabetes Mellitus, Type 2, Renal Insufficiency
What this study did
NCT01370005 · Boehringer Ingelheim
2011-06 – 2012-07 · Diabetes Mellitus, Type 2, Hypertension
What this study did
NCT01210001 · Boehringer Ingelheim
2010-09 – 2012-04 · Diabetes Mellitus, Type 2
What this study did
NCT01177813 · Boehringer Ingelheim
2010-07 – 2012-03 · Diabetes Mellitus, Type 2
What this study did
Phase 2/3 (19)
Chronic Kidney Disease
NCT07214818 · Mansoura University
2025-11-15 – 2026-09-06 · Nephrotic Syndrome
What this study did
NCT05373004 · Omar Tarek Elfarargi
2023-03 – 2024-05 · Diabetic Nephropathy Type 2
What this study did
Heart Failure
NCT05580510 · Instituto Nacional de Cardiologia Ignacio Chavez
2023-02-06 – 2024-03-29 · Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction
What this study did
Other / comorbidity
NCT07828002 · Martin Blomberg Jensen
2026-10-20 – 2029-04 · Paraffinoma, Granuloma, Foreign-Body
What this study did
NCT06715449 · University of East Anglia
2024-11-22 – 2029-03 · Embolic Stroke of Undetermined Source, Atrial Fibrillation New Onset
What this study did
NCT06506422 · University of Missouri-Columbia
2024-08-18 – 2029-02-28 · Aging, Arterial Stiffness
What this study did
NCT06030843 · Chulalongkorn University
2025-03-01 – 2026-12-31 · Empagliflozin in Cardiorenal Syndrome Type 1
What this study did
NCT06149793 · University of Minnesota
2024-01-08 – 2026-12-31 · Cystic Fibrosis-related Diabetes, Cystic Fibrosis
What this study did
NCT06469645 · University of East Anglia
2024-05-30 – 2026-07-24 · Moderate Aortic Valve Stenosis
What this study did
NCT07591077 · Ain Shams University
2024-11-20 – 2026-02-20 · Type 1 Diabetes, Nephropathy, Diabetic
What this study did
NCT06103279 · Ain Shams University
2023-11 – 2024-08 · Cancer
What this study did
NCT06140108 · SINA Health Education and Welfare Trust
2023-12-15 – 2024-06-30 · Polycystic Ovary Syndrome, Weight Gain, HbA1c
What this study did
NCT05430243 · Alexandria University
2022-04-21 – 2022-11-12 · Ascites Hepatic
What this study did
NCT04342819 · The University of The West Indies
2020-01-01 – 2021-12-31 · Platelet Dysfunction Due to Drugs
What this study did
NCT03202667 · University Hospital, Basel, Switzerland
2017-12-15 – 2021-12-06 · SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia
What this study did
NCT02874807 · University Hospital, Basel, Switzerland
2016-09-05 – 2019-01-14 · SIADH
What this study did
NCT03008551 · Hull University Teaching Hospitals NHS Trust
2017-08-18 – 2018-04-02 · Polycystic Ovary Syndrome
What this study did
NCT02729766 · University Hospital, Basel, Switzerland
2016-03 – 2016-08 · Inappropriate ADH Syndrome
What this study did
Phase 2 (77)
Atherosclerotic Cardiovascular Disease
NCT07749014 · Rehman Medical Institute - RMI
2026-09-01 – 2027-09-30 · ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI), Coronary Artery Disease
What this study did
NCT07898709 · Al-Azhar University
2027-01 – 2027-08 · No Reflow Phenomenon, Reperfusion Injuries, Myocardial, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, Coronary Artery Disease (CAD), PCI, Sodium Glucose Co-Transporter 2 Inhibitors, Empagliflozin, Dapagliflozin
What this study did
Chronic Kidney Disease
NCT07060417 · VA Office of Research and Development
2026-10-01 – 2029-09-30 · Non-diabetic Chronic Kidney Disease
What this study did
NCT07304817 · University Medical Center Groningen
2026-05-12 – 2028-02 · CKD, Cardiovascular Diseases, Heart Failure
What this study did
NCT06483074 · Chinese University of Hong Kong
2024-07-29 – 2027-10-31 · End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication, Sodium-glucose Cotransporter-2 Inhibitor, Residual Kidney Function
What this study did
NCT05786443 · NYU Langone Health
2024-01-31 – 2026-12-30 · End Stage Renal Disease
What this study did
NCT06926660 · Boehringer Ingelheim
2025-07-18 – 2026-08-14 · Chronic Kidney Disease
What this study did
NCT05638880 · Mostafa Bahaa
2022-12-20 – 2025-12-20 · Diabetic Nephropathies
What this study did
NCT06818305 · Jinling Hospital, China
2025-01-01 – 2025-10-01 · Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Nephrectomy, Chronic Kidney Disease(CKD)
What this study did
NCT05182840 · Boehringer Ingelheim
2022-01-11 – 2023-07-10 · Kidney Disease, Chronic
What this study did
NCT04143581 · Mario Negri Institute for Pharmacological Research
2021-09-03 – 2021-09-03 · Obesity, Non-diabetic Chronic Kidney Disease
What this study did
NCT03713190 · University of Pisa
2018-09-10 – 2020-03-15 · End Stage Renal Disease
What this study did
NCT03078101 · Medical University of Vienna
2017-04-15 – 2019-08-07 · Diabetic Kidney Disease, Diabetes Mellitus, Type 2, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
What this study did
Heart Failure
NCT06570473 · University of Alberta
2025-07-15 – 2027-06 · Pulmonary Hypertension, Right Ventricular Dysfunction, Right Heart Failure
What this study did
NCT05138575 · University of Pennsylvania
2022-01-24 – 2027-05-31 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT07372040 · Tanta University
2026-02-01 – 2027-02-01 · Acute Decompensated Heart Failure
What this study did
NCT07692256 · Ain Shams University
2025-12-01 – 2027-02-01 · Heart Failure
What this study did
NCT06012266 · Centre Hospitalier Universitaire Vaudois
2024-08 – 2025-08 · Heart Failure
What this study did
NCT07169981 · Ain Shams University
2023-07-12 – 2025-06-17 · Diabete Mellitus, Heart Failure, Remodeling, Left Ventricle
What this study did
NCT05042973 · Jacob Moller
2021-09-02 – 2025-01-23 · Obesity, Heart Failure
What this study did
NCT05084235 · Jacob Moller
2021-09-02 – 2025-01-16 · Heart Failure, Obesity
What this study did
NCT04049045 · Christian Schulze
2019-09-29 – 2021-06-29 · Acute Decompensated Heart Failure
What this study did
NCT03128528 · University of Erlangen-Nürnberg Medical School
2017-07-01 – 2020-04-30 · Chronic Heart Failure
What this study did
NCT03198585 · Morten Schou
2017-06-29 – 2020-01-17 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT03200860 · University Medical Center Groningen
2017-12-18 – 2019-09-18 · Heart Failure Acute, Heart Failure,Congestive, Heart Failure; With Decompensation
What this study did
Type 2 Diabetes
NCT05232071 · Inventiva Pharma
2022-06-29 – 2024-06-04 · NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
What this study did
NCT04702490 · Metacrine, Inc.
2020-12-15 – 2022-06 · NASH, NASH - Nonalcoholic Steatohepatitis, Type 2 Diabetes, Diabetes Type 2, Diabetes, Fatty Liver, Fatty Liver, Nonalcoholic, NAFLD
What this study did
NCT04535960 · University Health Network, Toronto
2019-03-14 – 2021-03-16 · Type 2 Diabetes Mellitus
What this study did
NCT03554200 · RWTH Aachen University
2018-06-11 – 2020-10-29 · Diabetes Mellitus, Type 2, Acute Heart Failure
What this study did
NCT02890745 · Henrik Enghusen Poulsen
2016-11 – 2020-01-22 · Diabetes Mellitus, Type 2
What this study did
NCT02632747 · Boehringer Ingelheim
2016-05-10 – 2019-07-02 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
What this study did
NCT03132181 · RWTH Aachen University
2017-04-24 – 2019-01-23 · Diabetes Mellitus Type 2 (T2DM)
What this study did
NCT01867307 · Boehringer Ingelheim
2013-06 – 2015-10 · Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01193218 · Boehringer Ingelheim
2010-09 – 2012-06 · Diabetes Mellitus, Type 2
What this study did
NCT00881530 · Boehringer Ingelheim
2009-03 – 2011-05 · Diabetes Mellitus, Type 2
What this study did
NCT00885118 · Boehringer Ingelheim
2009-04 – 2009-10 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07175051 · University of Illinois at Chicago
2026-04-08 – 2030-10 · Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
What this study did
NCT06992440 · Gustavo A Heresi, MD, MS
2025-06-26 – 2030-09 · Pulmonary Arterial Hypertension
What this study did
NCT06745063 · VA Office of Research and Development
2025-05-30 – 2029-12-31 · Obesity, Vascular Health
What this study did
NCT07756294 · Wake Forest University Health Sciences
2026-11 – 2028-04 · Alzheimer Disease
What this study did
NCT03867487 · Justin Ryder
2027-05-01 – 2028-02-01 · Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
What this study did
NCT06355310 · Justin Ryder
2025-04-10 – 2028-02-01 · Non-Alcoholic Fatty Liver Disease
What this study did
NCT07336797 · Abdelrahman Mahmoud
2025-09-01 – 2027-12-30 · Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)
What this study did
NCT06528405 · National Taiwan University Hospital
2024-11-21 – 2027-12 · Acute Kidney Injury
What this study did
NCT07864688 · Al-Azhar University
2026-12 – 2027-12 · Rheumatoid Arthritis (RA)
What this study did
NCT07883512 · Virginia Commonwealth University
2026-12-01 – 2027-09-30 · Breast Cancer, Supportive Care in Cancer
What this study did
NCT07146880 · National Taiwan University Hospital
2025-09-15 – 2027-09-21 · Brugada Syndrome (BrS)
What this study did
Phase 1/2 (7)
Chronic Kidney Disease
NCT05687058 · University of Mississippi Medical Center
2023-11-01 – 2026-06-20 · Kidney Failure, Chronic, Heart Failure
What this study did
Other / comorbidity
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT05972564 · Vanderbilt University Medical Center
2023-09-06 – 2027-12-30 · Obesity, Metabolic Syndrome
What this study did
NCT07947706 · Assiut University
2026-09-01 – 2027-05-01 · Empagliflozin, Hepatitis B, Steatosis
What this study did
NCT06113900 · Ain Shams University
2023-12-01 – 2025-01-30 · Lupus Nephritis
What this study did
NCT04907214 · Vanderbilt University Medical Center
2021-07-29 – 2023-12-08 · Obesity, Pre-diabetes
What this study did
NCT05977465 · Tanta University
2022-01-20 – 2023-08-03 · Diabetic Neuropathy Peripheral
What this study did
Phase 1 (93)
Atherosclerotic Cardiovascular Disease
NCT06578676 · Hyundai Pharm
2024-06-20 – 2024-11-30 · Type 2 Diabetes, Dyslipidemias
What this study did
Chronic Kidney Disease
NCT06430684 · Ann & Robert H Lurie Children's Hospital of Chicago
2024-08-23 – 2026-11-01 · Chronic Kidney Diseases, Pediatric Kidney Disease
What this study did
NCT05614115 · University of Utah
2023-03-21 – 2025-06-30 · End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic, Non-diabetic, Kidney Dysfunction, Kidney Failure, Hemodialysis
What this study did
NCT06483243 · Chong Kun Dang Pharmaceutical
2024-04-04 – 2024-05-17 · Type 2 Diabetes Mellitus
What this study did
NCT06204107 · Chong Kun Dang Pharmaceutical
2023-11-21 – 2023-12-06 · Type 2 Diabetes Mellitus
What this study did
Heart Failure
NCT06507657 · University of Minnesota
2024-12-12 – 2029-01-15 · Hypertension, Cardiovascular Diseases
What this study did
NCT05553938 · Yale University
2023-08-04 – 2026-08-14 · Heart Failure
What this study did
NCT03027960 · Yale University
2017-06-27 – 2019-06-01 · Heart Failure, Type II; Diabetes
What this study did
Type 2 Diabetes
NCT07053306 · The University of Texas Health Science Center at San Antonio
2025-04-29 – 2027-06-30 · Type 2 Diabetes
What this study did
NCT07053319 · The University of Texas Health Science Center at San Antonio
2026-05-11 – 2027-06-30 · Type 2 Diabetes
What this study did
NCT05960656 · The University of Texas Health Science Center at San Antonio
2023-10-05 – 2027-06-30 · Type 2 Diabetes
What this study did
NCT07053293 · The University of Texas Health Science Center at San Antonio
2025-01-07 – 2027-06-30 · Type 2 Diabetes
What this study did
NCT05057806 · The University of Texas Health Science Center at San Antonio
2021-01-13 – 2027-03-31 · Type2 Diabetes, Heart Failure With Preserved Ejection Fraction
What this study did
NCT06229678 · The University of Texas Health Science Center at San Antonio
2024-01-25 – 2027-03-01 · Type2diabetes, Heart Failure With Reduced Ejection Fraction
What this study did
NCT07872358 · Humanis Saglık Anonim Sirketi
2026-06-07 – 2026-10-07 · Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
What this study did
NCT07691203 · Humanis Saglık Anonim Sirketi
2026-03-07 – 2026-07-01 · Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
What this study did
NCT07694115 · Humanis Saglık Anonim Sirketi
2026-05-07 – 2026-07-01 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07372118 · Humanis Saglık Anonim Sirketi
2025-09-27 – 2026-01-07 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07266766 · Humanis Saglık Anonim Sirketi
2025-08-05 – 2025-10-06 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07213895 · Humanis Saglık Anonim Sirketi
2025-05-21 – 2025-09-18 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06932159 · Humanis Saglık Anonim Sirketi
2024-12-23 – 2025-04-08 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT04203927 · University of Virginia
2020-02-01 – 2023-11-30 · Type2 Diabetes, Insulin Sensitivity
What this study did
NCT05681273 · Chipscreen Biosciences, Ltd.
2023-02-17 – 2023-03-21 · T2DM
What this study did
NCT04869800 · Chong Kun Dang Pharmaceutical
2021-05-27 – 2021-06-15 · Type 2 Diabetes Mellitus
What this study did
NCT04431141 · Handok Inc.
2020-09-15 – 2021-01-25 · Type 2 Diabetes Mellitus
What this study did
NCT03766724 · Dong-A ST Co., Ltd.
2018-11-22 – 2019-01-18 · Type2 Diabetes
What this study did
NCT03565458 · LG Chem
2018-04-05 – 2018-12-22 · Type 2 Diabetes Mellitus
What this study did
NCT02854748 · Chong Kun Dang Pharmaceutical
2016-08 – 2016-09 · Diabetes Mellitus, Type II
What this study did
NCT02121483 · Boehringer Ingelheim
2014-06 – 2016-02 · Diabetes Mellitus, Type 2
What this study did
NCT01581658 · Boehringer Ingelheim
2012-04-01 – 2012-11-01 · Diabetes Mellitus, Type 2
What this study did
NCT01316341 · Boehringer Ingelheim
2011-03 – 2012-01 · Diabetes Mellitus, Type 2
What this study did
NCT01276288 · Boehringer Ingelheim
2011-01 – 2011-06 · Diabetes Mellitus, Type 2
What this study did
NCT01211197 · Boehringer Ingelheim
2010-10 – 2010-12 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07055282 · University of Chicago
2025-11-20 – 2028-11-01 · Kidney Stones
What this study did
NCT05360615 · Chulalongkorn University
2022-07-01 – 2027-07-01 · Empagliflozin in Post AKI Stage 2-3
What this study did
NCT06446531 · The University of Texas Health Science Center at San Antonio
2024-09-11 – 2027-07 · Pre-Diabetes, Weight, Body, Cardiovascular Diseases
What this study did
NCT07845630 · Boehringer Ingelheim
2026-10-14 – 2026-12-21 · Healthy
What this study did
NCT05610956 · Tanta University
2023-01-01 – 2026-12-01 · Ulcerative Colitis
What this study did
NCT06554301 · China National Center for Cardiovascular Diseases
2024-10-20 – 2026-12 · Pulmonary Arterial Hypertension
What this study did
NCT07331389 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2025-09-24 – 2026-06-13 · Overweight Subject, Healthy Subjects
What this study did
NCT06962826 · Boehringer Ingelheim
2025-05-27 – 2025-09-12 · Healthy
What this study did
NCT06828731 · Charles George VA Medical Center
2024-12-06 – 2025-09-05 · Prediabetes
What this study did
NCT07035457 · Boehringer Ingelheim
2025-07-02 – 2025-08-15 · Healthy
What this study did
NCT05078879 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-11-16 – 2025-05-21 · Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)
What this study did
Phase 4 (124)
Atherosclerotic Cardiovascular Disease
NCT07292909 · Hotel Dieu de France Hospital
2025-09-01 – 2027-09-30 · CAD - Coronary Artery Disease, Inflamation, PCI, SGLT 2 Inhibitors
What this study did
NCT06280976 · University of Louisville
2024-03-01 – 2025-01-01 · Coronary Artery Disease, Atherosclerosis, Heart Attack
What this study did
NCT04117763 · University of Sao Paulo
2019-10-04 – 2024-03-31 · Diabetes Mellitus, Type 2, Coronary Heart Disease, Arrythmia, Cardiac
What this study did
NCT04523064 · University of Sao Paulo General Hospital
2020-09-22 – 2024-01-30 · Diabetes Mellitus, Type 2, Coronary Artery Disease, Coronary Artery Bypass Surgery, Acute Kidney Injury
What this study did
NCT05037695 · University of Sao Paulo General Hospital
2021-07-21 – 2022-12 · Diabetes Mellitus, Type 2, Coronary Artery Disease, Acute Kidney Injury
What this study did
NCT04497792 · Research Institute for Complex Problems of Cardiovascular Diseases, Russia
2016-11 – 2019-11 · Coronary Artery Disease, Diabetes Mellitus, Percutaneous Coronary Intervention
What this study did
NCT03208465 · CHEOL WHAN LEE, M.D., Ph.D
2017-08-07 – 2019-08-01 · Diabetes Mellitus, Coronary Disease
What this study did
Chronic Kidney Disease
NCT06249945 · National Taiwan University Hospital
2024-03-05 – 2030-12-31 · Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis
What this study did
NCT06249932 · National Taiwan University Hospital
2024-03-13 – 2030-12-31 · Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
What this study did
NCT06013865 · VA Office of Research and Development
2024-04-05 – 2030-03-31 · Kidney Transplant, Chronic Kidney Disease
What this study did
NCT07775846 · Huijie Zhang
2026-11-03 – 2029-06-30 · Type 2 Diabetic Kidney Disease
What this study did
NCT07547878 · Baylor Research Institute
2026-04-08 – 2029-03-31 · Chronic Kidney Disease, Type 2 Diabetes
What this study did
NCT06642272 · Herlev and Gentofte Hospital
2024-10-10 – 2028-12-31 · Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Diseases
What this study did
NCT06110130 · Washington D.C. Veterans Affairs Medical Center
2024-02-02 – 2028-12-01 · Chronic Kidney Diseases
What this study did
NCT07074418 · Centre Hospitalier Universitaire de Nice
2026-08-25 – 2028-05 · Chronic Kidney Diseases
What this study did
NCT07155694 · Washington D.C. Veterans Affairs Medical Center
2026-10-01 – 2027-08 · Diabetic Kidney Disease
What this study did
NCT05671991 · Yale University
2023-03-01 – 2026-12-31 · End Stage Renal Disease on Dialysis
What this study did
NCT05305495 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2022-12-22 – 2026-03-10 · Acute Heart Failure, Chronic Kidney Diseases
What this study did
NCT06094920 · University Medical Center Groningen
2024-07-29 – 2025-09-24 · Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes, Diabetes Complications, Albuminuria, Chronic Kidney Diseases, Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, CKD, CKD Stage 3, CKD Stage 4
What this study did
NCT04243850 · Amsterdam UMC, location VUmc
2020-07-01 – 2022-03-01 · Diabetes Mellitus, Type 2, Chronic Kidney Diseases
What this study did
NCT04238702 · Amsterdam UMC, location VUmc
2020-11-04 – 2021-09-27 · Diabetes Mellitus, Type 2, Diabetic Kidney Disease
What this study did
NCT04215445 · National University of Malaysia
2019-12-01 – 2020-08 · Diabetic Retinopathy, Chronic Kidney Diseases, Diabetes Mellitus
What this study did
NCT03504566 · Steno Diabetes Center Copenhagen
2017-11-15 – 2019-06-01 · Diabetic Nephropathy Type 2
What this study did
Heart Failure
NCT06260059 · Anita Saraf
2024-09-17 – 2027-06-01 · Adult Congenital Heart Disease, Heart Failure
What this study did
NCT06055452 · China National Center for Cardiovascular Diseases
2024-01-19 – 2026-12-31 · Pre-Heart Failure, Hypertension
What this study did
NCT07926958 · Universidade do Porto
2024-03-11 – 2026-12 · Heart Failure, Acute Decompensated Heart Failure (ADHF)
What this study did
NCT05584319 · Zhijun Sun
2022-12-15 – 2025-10 · Heart Failure, Heart Failure With Preserved Ejection Fraction
What this study did
NCT05600387 · Zhijun Sun
2022-11-05 – 2025-10 · Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
What this study did
NCT06401343 · China National Center for Cardiovascular Diseases
2022-08-01 – 2025-08-01 · Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
What this study did
NCT06046612 · Maastricht University Medical Center
2023-02-13 – 2025-02-13 · Heart Failure With Preserved Ejection Fraction, Microvascular Dysfunction
What this study did
NCT05778084 · Alexandria University
2022-12-15 – 2024-12-15 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT05129722 · The George Institute
2022-10-01 – 2024-05-01 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT04583813 · Miulli General Hospital
2021-09 – 2024-04 · Atrial Fibrillation, Heart Failure, Obesity, Diabetes Mellitus
What this study did
NCT05139472 · University of Texas Southwestern Medical Center
2021-11-09 – 2024-02-19 · Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus
What this study did
NCT06632561 · Ashraf Wasfy Beshay Aziz
2021-07-26 – 2022-03-14 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT03271879 · Rambam Health Care Campus
2018-02-15 – 2020-06-01 · Heart Failure, Diabetes Mellitus, Arrythmia
What this study did
NCT03485092 · NHS Greater Glasgow and Clyde
2018-03-16 – 2020-03-28 · Heart Failure, Diabetes Mellitus
What this study did
NCT03030222 · Saint Luke's Health System
2017-07-05 – 2020-03-10 · Heart Failure
What this study did
Type 2 Diabetes
NCT07771010 · University Medical Centre Ljubljana
2026-04-16 – 2028-07-31 · Diabetes Type 2
What this study did
NCT06613854 · University Medical Centre Ljubljana
2024-10-01 – 2027-12 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT05164263 · Getz Pharma
2021-04-01 – 2027-08-31 · Type II Diabetes Mellitus, Efficacy, Self, Safety Issues
What this study did
NCT07365358 · Chong Kun Dang Pharmaceutical
2026-03 – 2027-08 · Diabete Type 2
What this study did
NCT06989723 · Seoul National University Bundang Hospital
2025-01-01 – 2027-06-30 · Type 2 Diabetes, Fatty Liver
What this study did
NCT07442006 · JW Pharmaceutical
2025-10-29 – 2027-03-31 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06706791 · Fazaia Ruth Pfau Medical College
2025-04-01 – 2026-12-01 · Chronic Heart Failure
What this study did
NCT07452913 · Bahria University
2026-01-01 – 2026-06-30 · Type 2 Diabetes Mellitus
What this study did
NCT06862739 · Nabiqasim Industries (Pvt) Ltd
2025-10-30 – 2026-06-30 · Diabetes Mellitus, Type 2 DM
What this study did
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT07120828 · Erbil Polytechnic University
2025-07-15 – 2026-03-15 · Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)
What this study did
Early phase / not applicable (40)
Atherosclerotic Cardiovascular Disease
NCT04541797 · The University of Hong Kong
2020-10-01 – 2025-02-28 · Type 2 Diabetes, Microvascular Coronary Artery Disease
What this study did
NCT06313008 · Damanhour University
2023-08-10 – 2024-10-10 · Coronary Artery Disease, Type 2 Diabetes
What this study did
Chronic Kidney Disease
NCT06187493 · Assiut University
2024-01-01 – 2025-12-31 · Diabetic Kidney Disease
What this study did
NCT07866235 · Lahore General Hospital
2023-10-11 – 2024-04-10 · Diabetic Nephropathies, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
What this study did
NCT04961931 · Medical University of Lodz
2019-01-01 – 2021-08-31 · Chronic Kidney Disease stage3
What this study did
Heart Failure
NCT07112274 · Damanhour University
2022-10-01 – 2025-07-30 · Heart Failure
What this study did
NCT05967156 · Shahid Beheshti University of Medical Sciences
2023-06-01 – 2025-06-03 · Heart Failure, Hemodialysis
What this study did
NCT07556094 · Medical University of Bialystok
2023-06-05 – 2025-05-09 · Obstructive Sleep Apnea (OSA), Sleep Apnea Syndrome, Obstructive, Heart Failure
What this study did
NCT06915870 · Fatima Maqsood
2024-07-12 – 2025-01-13 · Diabetes Mellitus, Heart Failure
What this study did
NCT06065280 · Damanhour University
2022-11-01 – 2024-12-30 · Heart Failure, Reduced Ejection Fraction Heart Failure
What this study did
Type 2 Diabetes
NCT05501483 · Karolinska Institutet
2023-02-08 – 2032-12-31 · Type 2 Diabetes
What this study did
NCT06519448 · Military University Hospital, Prague
2024-04-01 – 2027-12-31 · Non-alcoholic Steatohepatitis, Liver Diseases, Diabetes Mellitus, Type 2, Fibrosis, Liver
What this study did
NCT07303556 · Nazarbayev University
2024-12-18 – 2026-11-01 · Heart Failure, Diabete Type 2, Arterial Hypertension
What this study did
NCT05313529 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2022-10-08 – 2026-07-01 · Type 2 Diabetes Mellitus, Mild Cognitive Impairment
What this study did
NCT06187285 · Medanta, The Medicity, India
2024-01-01 – 2025-06-01 · Type 2 Diabetes
What this study did
NCT05417646 · Steno Diabetes Center Copenhagen
2022-06-22 – 2023-06-14 · Maturity-Onset Diabetes of the Young, Type 3, Type 2 Diabetes
What this study did
NCT05359341 · Sadat City University
2020-09-20 – 2022-01-10 · Diabete Type 2
What this study did
NCT02792400 · University Hospital, Gentofte, Copenhagen
2016-05 – 2018-07 · Type 2 Diabetes
What this study did
NCT03771781 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2018-04-16 – 2018-05-25 · Type 2 Diabetes
What this study did
NCT02686476 · Medanta, The Medicity, India
2016-03 – 2017-12 · Non Alcoholic Fatty Liver Disease
What this study did
NCT02964572 · Yonsei University
2016-11 – 2017-07 · Type2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT07141355 · University Hospital, Strasbourg, France
2025-12-12 – 2027-09-30 · Cardiogenic Shock
What this study did
NCT07678151 · Heart Health Research Center
2026-07-13 – 2027-08-31 · Hypertension (HTN)
What this study did
NCT07472920 · University of Sao Paulo
2026-11-12 – 2027-08 · Bipolar Disorder, Bipolar Depression, Insulin Resistance
What this study did
NCT06473844 · Hospital Authority, Hong Kong
2025-03-05 – 2027-02-28 · Sepsis, Inflammation, SGLT2 Inhibitors, Critically Ill, Organ Dysfunction Syndrome
What this study did
NCT06098625 · Medanta, The Medicity, India
2023-11-10 – 2025-12-01 · Diabetes Mellitus, Kidney Transplant; Complications
What this study did
NCT06095492 · Medanta, The Medicity, India
2023-10-30 – 2025-12-01 · Kidney Transplant; Complications, Diabetes Mellitus
What this study did
NCT07633054 · ADIUM
2025-09-10 – 2025-11-24 · Bioequivalence Study in Healthy Subjects
What this study did
NCT04918407 · Shahid Beheshti University of Medical Sciences
2022-01-01 – 2025-08-05 · Kidney Transplant; Complications
What this study did
NCT07633015 · ADIUM
2025-02-17 – 2025-04-29 · Bioequivalence Study in Healthy Subjects
What this study did
NCT07633028 · ADIUM
2025-02-10 – 2025-04-08 · Bioequivalence Study in Healthy Subjects
What this study did
NCT07633041 · ADIUM
2025-02-05 – 2025-04-04 · Bioequivalence Study in Healthy Subjects
What this study did
NCT06350903 · Matthieu Pelletier-Galarneau, MD MSc
2024-06-01 – 2024-11-01 · Myocardial Suppression
What this study did
NCT05694923 · Assiut University
2023-04-01 – 2024-04-01 · Fatty Liver Disease
What this study did
NCT04520646 · Huashan Hospital
2020-09-01 – 2022-08-31 · Acromegaly, Cardiomyopathies
What this study did
NCT05229796 · Mutah University
2021-05-17 – 2021-12-12 · Pharmacokinetic Parameters
What this study did
NCT03510000 · Samuel Lunenfeld Research Institute, Mount Sinai Hospital
2018-05-15 – 2019-11-21 · Type1diabetes
What this study did
NCT03591991 · Chinese PLA General Hospital
2018-10-01 – 2019-09-01 · Reperfusion Injury, Myocardial
What this study did
NCT04061473 · University Hospital, Gentofte, Copenhagen
2019-04-02 – 2019-08-20 · Diabetes After Total Pancreatectomy
What this study did
NCT03200782 · University Hospital, Basel, Switzerland
2017-05-30 – 2018-09-21 · Postprandial Hypoglycemia, Bariatric Surgery, Late Dumping Syndrome
What this study did
Used as active comparator (21)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (10)
Atherosclerotic Cardiovascular Disease
NCT04602754 · EMS
2023-12-01 – 2027-09 · Dyslipidemia Associated With Type II Diabetes Mellitus
What this study did
NCT04603508 · EMS
2023-03 – 2025-08 · Type 2 Diabetes Mellitus, Dyslipidemia
What this study did
Heart Failure
NCT05364190 · October 6 University
2022-06-04 – 2024-03-01 · Chronic Heart Failure, Acute Heart Failure, Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT05028140 · EMS
2024-10-08 – 2027-09 · Type II Diabetes
What this study did
NCT04670666 · EMS
2024-11-18 – 2027-06 · Type 2 Diabetes Mellitus
What this study did
NCT05444153 · Novo Nordisk A/S
2022-10-06 – 2025-08-29 · Diabetes Mellitus, Type 2
What this study did
NCT04970108 · EMS
2023-08 – 2025-05 · Hypertension Associated, Type II Diabetes Mellitus
What this study did
NCT02863328 · Novo Nordisk A/S
2016-08-10 – 2018-03-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01422876 · Boehringer Ingelheim
2011-08 – 2013-09 · Diabetes Mellitus, Type 2
What this study did
Phase 2 (2)
Type 2 Diabetes
NCT03462069 · Sanofi
2018-03-12 – 2019-04-18 · Diabetes Mellitus
What this study did
NCT03152552 · Novartis Pharmaceuticals
2017-07-25 – 2018-06-06 · Diabetes Mellitus and Heart Failure
What this study did
Phase 1 (4)
Other / comorbidity
NCT07102719 · Handok Inc.
2025-09-10 – 2025-10-20 · Healthy Volunteers
What this study did
NCT06889350 · Handok Inc.
2025-03-26 – 2025-05-07 · Healthy Volunteers
What this study did
NCT06339788 · Handok Inc.
2024-05-10 – 2024-06-12 · Healthy Volunteers
What this study did
NCT01328184 · Boehringer Ingelheim
2011-04 – 2011-07 · Healthy
What this study did
Phase 4 (4)
Type 2 Diabetes
NCT06642623 · Yonsei University
2024-01-22 – 2030-12-31 · Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases
What this study did
NCT07939750 · Allied Hospital Faisalabad
2026-12-01 – 2028-01-31 · Type 2 Diabetes Mellitus (DM)
What this study did
Other / comorbidity
NCT06410352 · University Medical Center, Kazakhstan
2024-03-01 – 2026-07-31 · Metabolic Syndrome
What this study did
NCT02768220 · Northwell Health
2017-12-01 – 2018-12 · SGLT-2 Inhibitors, Advanced Glycation End Products, Diabetes
What this study did
Early phase / not applicable (1)
Other / comorbidity
Appears in other studies (4)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (4)
Chronic Kidney Disease
NCT06531824 · Boehringer Ingelheim
2024-08-30 – 2026-12-31 · Kidney Disease, Chronic
What this study did
Heart Failure
NCT06424288 · Boehringer Ingelheim
2024-06-17 – 2028-05-22 · Heart Failure
What this study did
Type 2 Diabetes
NCT07064473 · Boehringer Ingelheim
2025-07-22 – 2029-12-21 · Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Chronic Kidney Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Empagliflozin (Jardiance): this drugApprovedSmall moleculeSGLT2Reliable signal
NCT03594110: Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met.
NCT05373680: Adjusted mean difference in eGFR decline vs standard-of-care control: metformin +8.91 ± 1.92 (p<0.001); empagliflozin +5.1 ± 1.89 (p=0.03) — both halted CKD progression vs control.
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Reliable signal
NCT03436693: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029)
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT03036150: Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001
Difelikefalin (Korsuva)ApprovedPeptideKappa-opioid receptor (agonist, peripherally restricted)Reliable signal
NCT03636269: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 54% (95% CI 43.9 to 63.9) vs Placebo 42.2% (95% CI 32.5 to 52.5)
NCT03422653: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 51% (95% CI 42.9 to 58.9) vs Placebo 27.6% (95% CI 20.2 to 36.6)
Etelcalcetide (Parsabiv)ApprovedPeptideCalcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cellsPartial signal
NCT01785849: Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).): Etelcalcetide 74% vs Placebo 8.3%
NCT01788046: Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).): Etelcalcetide 75.3% vs Placebo 9.6%
Extended-Release Calcifediol (Rayaldee)ApprovedSmall moleculeVitamin D receptor (VDR), via conversion to calcitriolPartial signal
NCT01704079: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline (Approximately 6 months): CTAP101 30 μg Capsules 49/144 (34.0%) vs Sugar Pill to CTAP101 30 μg 5/72 (6.9%)
NCT01651000: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values (Approximately 6 months): CTAP101 30 μg Capsules 46/141 (32.6%) vs Sugar Pill to CTAP101 30 μg Capsule 6/72 (8.3%)
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT00317239: Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL (anytime during the study): Ferric Carboxymaltose (FCM) 87/144 vs Ferrous Sulfate Tablets 35/101
Ferric Derisomaltose (Monoferric / Monofer)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT02940860: Change in Hemoglobin (Hb) From Baseline to Week 8 (Baseline to week 8): Iron Isomaltoside/Ferric Derisomaltose 1.22 g/dL (95% CI 1.14 to 1.31) vs Iron Sucrose 1.14 g/dL (95% CI 1.03 to 1.26)
NCT01102413: Change in Hemoglobin (Hb) Concentration From Baseline to Week 4. (Baseline, 4 weeks): Monofer 0.57 g/dL (range -3.1 to 4) vs Iron Sulphate 0.35 g/dL (range -3.7 to 3.9)
Ferric Pyrophosphate Citrate (Triferic)
ApprovedUS marketing discontinued
Small moleculeIron-replacement therapy delivered via dialysateWeak signalNo reviewed efficacy summary in this indication
Ferumoxytol (Feraheme)ApprovedNanoparticleIV iron replacement therapyPartial signal
NCT00255424: Primary endpoint (hemoglobin change at day 35): ferumoxytol +0.82 ± 1.24 g/dl vs oral iron +0.16 ± 1.02 g/dl, P<0.0001, in favor of ferumoxytol. CT.gov's own citation list ties this Spinowitz 2008 publication specifically to NCT00255424 (not its twin trial NCT00255437).
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT05047263: Total eGFR slope, baseline to month 32 (FIND-CKD): -3.3 mL/min/1.73m2/year finerenone vs -4.0 mL/min/1.73m2/year placebo; between-group difference 0.7 mL/min/1.73m2/year (95% CI 0.3-1.1; p<0.001)
NCT02540993: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death (From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months): Finerenone 504/2833 vs Placebo 600/2841
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
Sucroferric Oxyhydroxide (Velphoro)ApprovedSmall moleculeDietary phosphatePartial signal
NCT03644264: Change in serum phosphorus from baseline to week 12: -0.71 (0.60) mmol/L with sucroferric oxyhydroxide vs -0.63 (0.52) mmol/L with sevelamer; difference in least squares means 0.08 mmol/L (95% CI -0.02, 0.18), meeting the pre-specified non-inferiority margin of -0.34 mmol/L
NCT01464190: Change From Baseline and Levels at Each Time Point for Serum Phosphorus (Every 4 weeks from baseline to Week 28): PA21 — Change from Baseline to Week 4 (n = 346, 236): -0.2 mg/dL (Standard Deviation 1.33); Change from Baseline to Week 8 (n = 325, 238): -0.2 mg/dL (Standard Deviation 1.38); Change from Baseline to Week 12 (n = 322, 242): 0 mg/dL (Standard Deviation 1.43); Change from Baseline to Week 16 (n = 313, 228): 0 mg/dL (Standard Deviation 1.57); Change from Baseline to Week 20 (n = 300, 221): 0 mg/dL (Standard Deviation 1.46); Change from Baseline to Week 24 (n = 286, 208): 0.1 mg/dL (Standard Deviation 1.53); Chnage from Baseline to Week 28 (n = 287, 210): 0.2 mg/dL (Standard Deviation 1.52); Change from Baseline to Endpoint (n = 384, 260): 0.1 mg/dL (Standard Deviation 1.62) vs Sevelamer Carbonate — Change from Baseline to Week 4 (n = 346, 236): -0.1 mg/dL (Standard Deviation 1.47); Change from Baseline to Week 8 (n = 325, 238): 0.1 mg/dL (Standard Deviation 1.56); Change from Baseline to Week 12 (n = 322, 242): 0.2 mg/dL (Standard Deviation 1.55); Change from Baseline to Week 16 (n = 313, 228): 0.2 mg/dL (Standard Deviation 1.75); Change from Baseline to Week 20 (n = 300, 221): 0.1 mg/dL (Standard Deviation 1.44); Change from Baseline to Week 24 (n = 286, 208): 0.2 mg/dL (Standard Deviation 1.78); Chnage from Baseline to Week 28 (n = 287, 210): 0.2 mg/dL (Standard Deviation 1.76); Change from Baseline to Endpoint (n = 384, 260): 0.3 mg/dL (Standard Deviation 1.79)
Taurolidine / Heparin (Defencath / Neutrolin)ApprovedSmall moleculeAntimicrobial/antithrombotic catheter lock solutionReliable signal
NCT02651428: Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD): Final Analysis (The event time was the number of days from randomization until the occurrence of a CAC-Adjudicated CRBSI or until the subject was censored. The mean participant duration of exposure to study drug was 174 days (range 4-884 days).): Neutrolin Arm 9/397 vs Heparin Arm 32/398
Tenapanor (Xphozah)ApprovedSmall moleculeNHE3 (sodium/hydrogen exchanger isoform 3)Partial signal
NCT03427125: Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder Population (12 weeks (randomized withdrawal period)): Tenapanor 10 mg, 20 mg, 30 mg BID 0.43 mg/dL (Standard Deviation 0.199) | Placebo 1.8 mg/dL (Standard Deviation 0.196)
NCT02675998: Primary 4-week randomized-withdrawal serum phosphate change: pooled tenapanor 1.4 mg/dL vs placebo 0.6 mg/dL (p=0.01).
Vadadustat (Vafseo)ApprovedSmall moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT02680574: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 0.41 Grams per deciliter (g/dL) (Standard Error 0.036) vs Darbepoetin Alfa 0.42 Grams per deciliter (g/dL) (Standard Error 0.037)
NCT02648347: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 1.43 g/dL (Standard Error 0.046) vs Darbepoetin Alfa 1.38 g/dL (Standard Error 0.047)
AND017Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signalNo reviewed efficacy summary in this indication
Anrikefon (HSK21542)Phase 3PeptideKappa-opioid receptor (agonist, peripherally restricted)Reliable signal
NCT05135390: Proportion with ≥4-point WI-NRS improvement at week 12: anrikefon 37% vs placebo 15% (P<0.001)
AP301 (fiber-Iron Phosphate Binder)Phase 3Small moleculeIron-based intestinal phosphate binderPartial signal
NCT07030595: Primary 1, serum phosphate change baseline to week 12, AP301 vs sevelamer carbonate (non-inferiority, margin 0.19 mmol/L): LSM difference -0.02 mmol/L (95% CI -0.10 to 0.06), upper bound below margin, met. Primary 2, serum phosphate change week 24 to week 27, AP301 maintenance dose vs low dose: LSM difference -0.58 mmol/L (95% CI -0.69 to -0.47; P<0.001), equivalent to -1.8 mg/dL, met.
ApecotrepPhase 3Small moleculeTRPC6 (transient receptor potential cation channel subfamily C member 6)Partial signal
NCT05213624: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 (At baseline and Week 12.): BI 764198 20 mg 48.9 Predicted percentage of patients (95% CI 29.2 to 68.6) | BI 764198 40 mg 16 Predicted percentage of patients (95% CI -1.5 to 33.5) | BI 764198 80 mg 38.5 Predicted percentage of patients (95% CI 12.2 to 64.8) vs Placebo 11.4 Predicted percentage of patients (95% CI -2.3 to 25.2)
NCT04176536: Single 40mg dose, matched-pair renal-impairment vs normal-renal-function design (NCT04176536): AUC increased 48% (moderate) / 78% (severe) renal impairment vs healthy controls; Cmax increased 14% / 12%; terminal half-life 12.7-17.4h independent of dose and renal function.
AST-120 (Kremezin)Phase 3Small moleculeOral spherical carbon adsorbentPartial signal
NCT00500682: Primary endpoint, time to composite of dialysis initiation, kidney transplantation or serum creatinine doubling: hazard ratio 1.03 (95% CI 0.84 to 1.27), P=0.78; events AST-120 178/500 vs placebo 177/502. missed
NCT00501046: Primary endpoint, time to composite of dialysis initiation, kidney transplantation or serum creatinine doubling: hazard ratio 0.91 (95% CI 0.74 to 1.12), P=0.37; events AST-120 172/500 vs placebo 183/497. missed
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signal
NCT04595370: Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): AZD9977 15 mg + Dapagliflozin 10 mg -56.391% (95% CI -71.528--33.207) vs AZD9977 50 mg + Dapagliflozin 10 mg -42.085% (95% CI -64.174--6.376) vs AZD9977 150 mg + Dapagliflozin 10 mg -58.047% (95% CI -73.560--33.430) vs AZD9977 150 mg -45.01% (95% CI NA-NA) vs Dapagliflozin 10 mg -34.318% (95% CI -58.204-3.220) vs Placebo 230.32% (95% CI NA-NA); p=0.3645 (AZD9977 15 mg + Dapagliflozin 10 mg vs AZD9977 50 mg + Dapagliflozin 10 mg vs AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg) missed
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
BHV-1400Phase 3Biologic (subtype unspecified)Gd-IgA1 (galactose-deficient IgA1)not yet gradedNo reviewed efficacy summary in this indication
Bixalomer (Kiklin)Phase 3Small moleculePhosphate binderWeak signal
NCT01742585: Change in serum phosphorus, baseline to end of treatment (12 weeks): bixalomer -0.78 mg/dL (95% CI -0.98, -0.57) vs placebo 0.20 mg/dL (95% CI -0.00, 0.41); mean difference -0.98 mg/dL (95% CI -1.27, -0.69), P < 0.001.
NCT01742611: Mean serum phosphorus: 5.15 mg/dL at baseline, decreasing to 4.67 mg/dL at Week 12, reaching 4.58 mg/dL at Week 48 of open-label bixalomer treatment
Colestilan (Cholebine / BindRen)Phase 3Small moleculePhosphate binderPartial signal
NCT00542815: Primary outcome, change in serum phosphorus from baseline to week 52 in an open-label long-term safety study (no comparator test): -1.23 mg/dL (colestilan from E07/E08), -1.47 mg/dL (colestilan from E07) and -2.26 mg/dL (sevelamer from E07) (CT.gov posted results).
NCT00416520: Serum phosphorus at week 16 (end of the 4-week placebo-controlled withdrawal): 0.43 mmol/L (1.32 mg/dL) lower with colestilan than with placebo (P<0.001) (Locatelli et al., Nephrol Dial Transplant 2014).
Desidustat (Oxemia)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT04215120: Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382)
NCT04012957: Change in hemoglobin baseline to week 16-24: desidustat +1.95 g/dL vs darbepoetin +1.83 g/dL (difference 0.11 g/dL, 95% CI -0.12 to 0.34), met prespecified noninferiority margin of -0.75 g/dL; hemoglobin responders 77.78% desidustat vs 68.48% darbepoetin (p=0.0181)
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
EnarodustatPhase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT06016036: Mean Hb change from baseline averaged over Weeks 7-9: enarodustat +15.99 g/L (SD 9.46) vs placebo +0.14 g/L (SD 8.08); P<0.001
NCT04027517: 평가기간 중 투여군간 차이 [95% 신뢰구간] -0.19 [-0.46, 0.08] (이 약 투여군 N=57 평가기간 중 Hb 농도 평균 10.65 g/dL, 다베포에틴 알파 투여군 N=67 10.83 g/dL; 베이스라인 10.73 vs 10.68 g/dL; 비열등성 마진 -1.0 g/dL)
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
HRS-1780Phase 3Small moleculeMineralocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Imlifidase (Idefirix)Phase 3Protein / enzyme therapeuticImmunoglobulin G (IgG), all four human subclassesWeak signal
NCT02790437: Crossmatch conversion (positive to negative) within 24 hours of IdeS dosing: 17 of 19 patients converted; 2 of 19 did not.
Iptacopan (Fabhalta)Phase 3Small moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
NCT03373461: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 (Baseline and Day 90): LNP023 10 mg BID 0.85 Ratio to baseline (95% CI 0.77-0.93) vs LNP023 50 mg BID 0.80 Ratio to baseline (95% CI 0.73-0.87) vs LNP023 100 mg BID - Part 2 0.76 Ratio to baseline (95% CI 0.70-0.81) vs LNP023 200 mg BID 0.69 Ratio to baseline (95% CI 0.61-0.77) vs Placebo 0.88 Ratio to baseline (95% CI 0.80-1.00); p=0.038 (LNP023 10 mg BID vs LNP023 50 mg BID vs LNP023 100 mg BID - Part 2 vs LNP023 200 mg BID vs Placebo)
Janagliflozin (Huiyoujing)
Phase 3(overall)
Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
JR-131Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signal
NCT02912494: Change in Hb level from baseline to end of treatment (24 weeks): JR-131 −0.42 ± 0.73 g/dL vs darbepoetin alfa −0.43 ± 0.77 g/dL; between-group difference 0.01 g/dL (95% CI −0.19 to 0.20), within the prespecified equivalence margin of −0.5 to 0.5 g/dL
Loncipoetin Alfa (NuPIAO)Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signal
NCT05211167: Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given.
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
MolidustatPhase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT03543657: Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established
NCT03350347: Mean Hb during the week 30-36 evaluation period: 11.67 g/dL molidustat vs 11.53 g/dL darbepoetin; LS mean difference 0.13 g/dL (95% CI -0.15 to 0.40), inside the 1.0 g/dL noninferiority margin.
MT1013Phase 3PeptideCaSR; OGPPartial signalNo reviewed efficacy summary in this indication
NNG-DEPO (Stimus)Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signalNo reviewed efficacy summary in this indication
Patiromer (Veltassa)Phase 3Small moleculeGastrointestinal potassium binderPartial signal
NCT01810939: Change in Serum Potassium From Part A Baseline to Part A Week 4 (Part A Baseline to Part A Week 4): Part A Patiromer -1.01 mEq/L (Standard Error 0.031)
Pegmolesatide (HS-20039)Phase 3PeptideErythropoietin receptor (EPO-R)Reliable signal
NCT03903809: Mean Hb change from baseline: pegmolesatide +19.2 g/L vs epoetin alfa +15.4 g/L; between-group difference 3.8 g/L (95% CI 0.7-6.9), noninferiority margin -10 g/L
NCT03902691: Mean change in hemoglobin (baseline to evaluation period): +0.07 g/dL pegmolesatide vs -0.22 g/dL epoetin alfa; between-group difference 0.29 g/dL (95% CI 0.11-0.47), non-inferiority verified
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
Rilparencel (Neo-Kidney Augment / REACT)Phase 3Cell therapySelected renal cells (autologous, paracrine)Weak signal
NCT05018416: Primary endpoint (difference in annual eGFR slope, pre- vs post-treatment): Group 1 (n=24) -5.8 to -1.3 mL/min/1.73m2, difference 4.6 per year, 78% improvement, P < .001; Group 2 (n=25) -3.4 to -1.7 mL/min/1.73m2, difference 1.7 per year, 50% improvement, P = .085
Roxadustat (Evrenzo)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Reliable signal
NCT01750190: Mean hemoglobin change over Weeks 28-52: 2.00 g/dL roxadustat vs 0.16 g/dL placebo; least-squares mean difference 1.85 g/dL (95% CI 1.735-1.967; p<0.0001). Hemoglobin response during the first 24 weeks: 523/608 roxadustat vs 20/305 placebo; odds ratio 77.56 (95% CI 44.73-134.48; p<0.0001).
NCT01887600: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response (Baseline to week 24): Roxadustat 79.2% (95% CI 74.8 to 83.1) vs Placebo 9.9% (95% CI 6.1 to 14.8)
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
SC0062Phase 3Small moleculeEndothelin receptor type A (ETA)not yet gradedNo reviewed efficacy summary in this indication
SHR6508Phase 3Small moleculeCalcium-sensing receptor (CaSR)Weak signalNo reviewed efficacy summary in this indication
Sodium Zirconium Cyclosilicate (Lokelma)Phase 3Small moleculeGastrointestinal potassium binderPartial signal
NCT05056727: Total eGFR Slope (Coprimary Analysis #1) (Baseline (Maintenance phase) to visit 17 (week 69)): Maintenance Phase: SZC -5.2975 mL/min/(1.73 m2)/yr (95% CI -6.6854 to -3.9097) vs Maintenance Phase: Placebo -4.5622 mL/min/(1.73 m2)/yr (95% CI -5.9969 to -3.1275) missed
Somatropin (Jintropin)Phase 3Biologic (subtype unspecified)Growth hormone receptorPartial signal
NCT03535415: HT-SDS change at week 52: +0.75 (rhGH-treated) vs +0.17 (untreated control), reported as statistically significant; enrollment (68) and design match NCT03535415 exactly, and the paper is indexed against this NCT.
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)Partial signal
NCT03242018: Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo (Baseline to Week 26): Sotagliflozin 400 mg -0.4 percentage of HbA1c (Standard Error 0.131) vs Placebo -0.11 percentage of HbA1c (Standard Error 0.151) missed
NCT03242252: Change From Baseline in HbA1c at Week 26 (Baseline to Week 26): Sotagliflozin 200 mg -0.32 percentage of HbA1c (Standard Error 0.06) | Sotagliflozin 400 mg -0.46 percentage of HbA1c (Standard Error 0.06) vs Placebo -0.22 percentage of HbA1c (Standard Error 0.061)
Upacicalcet (UPASITA)Phase 3Small moleculeCalcium-sensing receptor (CaSR)Partial signal
NCT05836220: PATH-2, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 43.5% versus 17.4%, for a difference in proportions of 26.1% (95% confidence interval, 17.4 to 34.8, P < 0.001) (J Am Soc Nephrol, 2026-10-23).
NCT05832931: PATH-1, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 42.1% versus 16.8%, for a difference in proportions of 25.3% (95% confidence interval, 16.2 to 34.5, P < 0.001) (J Am Soc Nephrol, 2026-10-23).
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)Partial signal
NCT06531824: Discontinued by Boehringer Ingelheim on an independent Data Monitoring Committee recommendation: accumulating data did not support a meaningful expectation of benefit on the primary composite endpoint vs empagliflozin alone (September 2026). missed
NCT05182840: Change in log UACR at week 14 (all patients): 10 mg -0.553 vs placebo -0.066 (difference -0.486, 95% CI -0.660 to -0.313, p<0.0001); 20 mg -0.487 (difference -0.421, 95% CI -0.596 to -0.246, p<0.0001); 3 mg -0.235 (difference -0.168, 95% CI -0.337 to -0.000, p=0.0499). Adjusted median percent change: 10 mg -42.5% vs placebo -6.4%.
Zibotentan + DapagliflozinPhase 3Small moleculeEndothelin A receptor, SGLT2not yet gradedNo reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
InaxaplinPhase 2/3Small moleculeAPOL1 (Apolipoprotein L1)Weak signal
NCT06794996: Single-group Phase 2b AMPLIFIED: UACR -42.7% (cohort 1) and -17.3% (AMKD with type 2 diabetes) from baseline at Week 13 (Vertex, 2026-09-22).
NCT04340362: The primary outcome was the percent change from the baseline urinary protein-to-creatinine ratio at week 13 in participants with at least 80% adherence to inaxaplin therapy. Sixteen participants were enrolled; among the 13 who were treated and met the adherence threshold, the mean change from baseline at week 13 was -47.6% (95% confidence interval, -60.0 to -31.3).
KT-301Phase 2/3Microbiome therapeuticProbiotic live biotherapeuticnot yet gradedNo reviewed efficacy summary in this indication
AB002Phase 2Protein / enzyme therapeuticProtein CPartial signal
NCT03963895: Primary outcomes: 40 registered safety and tolerability counts (treatment-related adverse events, access-site bleeding, ECG, anti-thrombin antibodies, vital signs and laboratory changes); safety outcome, no formal efficacy test. Treatment-related TEAEs: 0 in each AB002 dose group and 0 with placebo (CT.gov posted results).
ALN-ANG3Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
Avacopan (Tavneos)Phase 2Small moleculeComplement C5a receptor 1 (C5aR1/CD88)Weak signalFeatured results are pharmacokinetic only in this race
CagrilintidePhase 2PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Partial signalNo reviewed efficacy summary in this indication
CU01-1001Phase 2Small moleculeNrf2 / TGF-betaPartial signal
NCT05718375: Change in UACR at Week 24 vs placebo: low-dose -21.45% (p=0.0448); high-dose -22.21% (p=0.0313)
GruticibartPhase 2Monoclonal antibodyFactor XIPartial signal
NCT03612856: Treatment-related TEAEs: 0/8 AB023 0.25 mg/kg, 0/8 AB023 0.5 mg/kg, and 0/8 placebo; post-dose vascular-access bleeding events: 0 AB023 0.25 mg/kg, 5 AB023 0.5 mg/kg, and 3 placebo.
HenagliflozinPhase 2Small moleculeSodium-glucose cotransporter 2 (SGLT2)not yet gradedNo reviewed efficacy summary in this indication
HS-10390Phase 2Small moleculeAngiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)not yet gradedNo reviewed efficacy summary in this indication
QiShenYiQiPhase 2BotanicalTraditional Chinese medicine (multi-component)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 2Small moleculeVasopressin V2 receptornot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 67 furthest-along competitors are listed; 32 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(88 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Jardiance (Empagliflozin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (18)
November 2026 (2)
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2026-11-30 · NCT05057806 · CT.gov ↗
What to watch
Phase 2/3Empagliflozin in Cardiorenal Syndrome Type 1Recruiting
Est. primary completion 2026-11-30 · NCT06030843 · CT.gov ↗
What to watch
December 2026 (16)
Phase 1Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2026-12 · NCT06554301 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2026-12 · NCT07093476 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2026-12 · NCT07311551 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2026-12-01 · NCT07692256 · CT.gov ↗
What to watch
Phase 2Cirrhosis, Liver FailureRecruiting
Est. primary completion 2026-12-01 · NCT05726032 · CT.gov ↗
What to watch
Phase 1HealthyRecruiting
Est. primary completion 2026-12-11 · NCT07845630 · CT.gov ↗
What to watch
Phase 2Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)Recruiting
Est. primary completion 2026-12-30 · NCT07336797 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2026-12-30 · NCT05786443 · CT.gov ↗
What to watch
Phase 4Lupus Nephritis (LN)Recruiting
Est. primary completion 2026-12-30 · NCT07700940 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2026-12-31 · NCT05392764 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT06989723 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT05164263 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2026-12-31 · NCT06055452 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2026-12-31 · NCT05671991 · CT.gov ↗
What to watch
Phase 4Heart FailureActive not recruiting
Est. primary completion 2026-12-31 · NCT06260059 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesEnrolling by invitation
Est. primary completion 2026-12-31 · NCT06519448 · CT.gov ↗
What to watch
2027 (42)
January 2027 (1)
Phase 3Diabetes Type 1Recruiting
Est. primary completion 2027-01 · NCT06894784 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Heart FailureRecruiting
Est. primary completion 2027-02-01 · NCT07372040 · CT.gov ↗
What to watch
Early phase / not applicableSepsis, Inflammation, SGLT2 Inhibitors, Critically Ill, Organ Dysfunction SyndromeRecruiting
Est. primary completion 2027-02-28 · NCT06473844 · CT.gov ↗
What to watch
March 2027 (4)
Phase 3Cardiogenic ShockRecruiting
Est. primary completion 2027-03-16 · NCT05879276 · CT.gov ↗
What to watch
Phase 2DMD-associated Dilated CardiomyopathyNot yet recruiting
Est. primary completion 2027-03-31 · NCT06643442 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2027-03-31 · NCT06570473 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-03-31 · NCT07442006 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1/2Empagliflozin, Hepatitis B, SteatosisEnrolling by invitation
Est. primary completion 2027-04-01 · NCT07947706 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2027-04-16 · NCT07107945 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2027-04-30 · NCT07038356 · CT.gov ↗
What to watch
Early phase / not applicableHypertension (HTN)Not yet recruiting
Est. primary completion 2027-04-30 · NCT07678151 · CT.gov ↗
What to watch
May 2027 (4)
Phase 4Autosomal Dominant Polycystic KidneyActive not recruiting
Est. primary completion 2027-05 · NCT06391450 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-05-01 · NCT05715814 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2027-05-31 · NCT05138575 · CT.gov ↗
What to watch
Phase 2Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes MellitusRecruiting
Est. primary completion 2027-05-31 · NCT06729996 · CT.gov ↗
What to watch
June 2027 (7)
Phase 2Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2027-06 · NCT07898709 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07053306 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07053319 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT05960656 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07053293 · CT.gov ↗
What to watch
Phase 1/2Obesity, Metabolic SyndromeRecruiting
Est. primary completion 2027-06-30 · NCT05972564 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-06-30 · NCT07292909 · CT.gov ↗
What to watch
July 2027 (4)
Phase 1Pre-Diabetes, Weight, Body, Cardiovascular DiseasesRecruiting
Est. primary completion 2027-07 · NCT06446531 · CT.gov ↗
What to watch
Phase 2Acute Kidney InjuryRecruiting
Est. primary completion 2027-07 · NCT06528405 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-07 · NCT07155694 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-07-31 · NCT06483074 · CT.gov ↗
What to watch
August 2027 (5)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-08 · NCT07365358 · CT.gov ↗
What to watch
Early phase / not applicableBipolar Disorder, Bipolar Depression, Insulin ResistanceRecruiting
Est. primary completion 2027-08 · NCT07472920 · CT.gov ↗
What to watch
Phase 4Atrial Fibrillation, SGLT2 Inhibitor, DC CardioversionRecruiting
Est. primary completion 2027-08-01 · NCT07776054 · CT.gov ↗
What to watch
Phase 2Brugada Syndrome (BrS)Not yet recruiting
Est. primary completion 2027-08-21 · NCT07146880 · CT.gov ↗
What to watch
Early phase / not applicableCardiogenic ShockRecruiting
Est. primary completion 2027-08-31 · NCT07141355 · CT.gov ↗
What to watch
September 2027 (3)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-09 · NCT06613854 · CT.gov ↗
What to watch
Phase 2Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2027-09-30 · NCT07749014 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Supportive Care in CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07883512 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Heart FailureRecruiting
Est. primary completion 2027-11 · NCT06024746 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Rheumatoid Arthritis (RA)Not yet recruiting
Est. primary completion 2027-12 · NCT07864688 · CT.gov ↗
What to watch
Phase 3Congenital Heart DiseaseRecruiting
Est. primary completion 2027-12 · NCT06955260 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-12-01 · NCT06110130 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2027-12-31 · NCT06249945 · CT.gov ↗
What to watch
Phase 4Chronic Hepatitis b, NAFLD, Cirrhosis, Fibrosis, Liver, Empagliflozin, SGLT2 InhibitorsActive not recruiting
Est. primary completion 2027-12-31 · NCT05147090 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-31 · NCT07771010 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2027-12-31 · NCT06249932 · CT.gov ↗
What to watch
2028 (15)
January 2028 (3)
Phase 2Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLDNot yet recruiting
Est. primary completion 2028-01-01 · NCT03867487 · CT.gov ↗
What to watch
Phase 2Non-Alcoholic Fatty Liver DiseaseRecruiting
Est. primary completion 2028-01-01 · NCT06355310 · CT.gov ↗
What to watch
Phase 3CardiotoxicityActive not recruiting
Est. primary completion 2028-01-01 · NCT05271162 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Heart FailureRecruiting
Est. primary completion 2028-02 · NCT07304817 · CT.gov ↗
What to watch
Phase 4Gout and HyperuricemiaRecruiting
Est. primary completion 2028-02-01 · NCT06674109 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Alzheimer DiseaseNot yet recruiting
Est. primary completion 2028-04 · NCT07756294 · CT.gov ↗
What to watch
May 2028 (1)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-05 · NCT07074418 · CT.gov ↗
What to watch
September 2028 (3)
Phase 4Blood Pressure, Endothelial DysfunctionNot yet recruiting
Est. primary completion 2028-09 · NCT07799441 · CT.gov ↗
What to watch
Phase 3PneumoniaRecruiting
Est. primary completion 2028-09-30 · NCT04381936 · CT.gov ↗
What to watch
Phase 3Empgliflozin Cardioprotective EffectNot yet recruiting
Est. primary completion 2028-09-30 · NCT07815808 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2/3Aging, Arterial StiffnessRecruiting
Est. primary completion 2028-10-31 · NCT06506422 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1Kidney StonesRecruiting
Est. primary completion 2028-11-01 · NCT07055282 · CT.gov ↗
What to watch
December 2028 (3)
Phase 4Partial Islet Function, TPIAT, DiabetesRecruiting
Est. primary completion 2028-12-01 · NCT07228195 · CT.gov ↗
What to watch
Phase 2Obesity, Vascular HealthRecruiting
Est. primary completion 2028-12-31 · NCT06745063 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2028-12-31 · NCT06642272 · CT.gov ↗
What to watch
2029 (8)
January 2029 (2)
Phase 1Heart FailureRecruiting
Est. primary completion 2029-01-15 · NCT06507657 · CT.gov ↗
What to watch
Phase 4Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors, CirrhosisRecruiting
Est. primary completion 2029-01-30 · NCT07322237 · CT.gov ↗
What to watch
February 2029 (1)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2029-02-28 · NCT07775846 · CT.gov ↗
What to watch
March 2029 (3)
Phase 2/3Paraffinoma, Granuloma, Foreign-BodyRecruiting
Est. primary completion 2029-03 · NCT07828002 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2029-03-31 · NCT07060417 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesEnrolling by invitation
Est. primary completion 2029-03-31 · NCT07547878 · CT.gov ↗
What to watch
August 2029 (1)
Phase 4Heart Transplant, Cardiovascular Disease, Kidney DiseaseRecruiting
Est. primary completion 2029-08-31 · NCT06625073 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaRecruiting
Est. primary completion 2029-10 · NCT07175051 · CT.gov ↗
What to watch
2030 (4)
March 2030 (1)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2030-03-31 · NCT06013865 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2030-07 · NCT06992440 · CT.gov ↗
What to watch
September 2030 (2)
Phase 3Kidney Stone, Nephrolithiasis, Dietary ExposureRecruiting
Est. primary completion 2030-09 · NCT06653738 · CT.gov ↗
What to watch
Phase 1/2Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Phase 3Coronary Microvascular Dysfunction (CMD)Not yet recruiting
Est. primary completion 2031-05 · NCT07533747 · CT.gov ↗
What to watch

See the full readout calendar ↗